Melanoma Clinical Trials in Illinois

Showing 141-160 of 311 trials

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490

The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced)

Advanced MelanomaMetastatic Melanoma

Bristol-Myers Squibb170 participantsStarted Sep 2012

Los Angeles, California, United States • Chicago, Illinois, United States • Lutherville, Maryland, United States +11 more locations

COMPLETEDPhase 3125 miles

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

NCT02678572

This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.

Melanoma, Ocular

Delcath Systems Inc.102 participantsStarted Feb 2016

Tucson, Arizona, United States • Palo Alto, California, United States • Tampa, Florida, United States +21 more locations

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Melanoma Trials in Other Cities

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Study in Subjects With Small Primary Choroidal Melanoma

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Neoadjuvant and Adjuvant Checkpoint Blockade

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

Other Conditions in Illinois